PF-Atlas › Clinical Trials › NCT00071461

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

bosentan · Phase 2

Registry ID
NCT00071461
Phase
Phase 2
Status
Completed
Drug / intervention
bosentan
Sponsor
Actelion
Start
2003-08
Enrollment
158
Locations
29

About this trial

Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis. Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic pulmonary fibrosis (IPF), a condition for which no established treatment is available. The present trial investigates a possible use of bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a new category of patients suffering from IPF. It was decided to offer Open Label treatment (bosentan) for patients willing to continue in the BUILD 1 study.

View NCT00071461 on ClinicalTrials.gov →

Explore related

All bosentan trialsAll IPF trials

Related trials

Bosentan — NCT00318175Bosentan — NCT00070590bosentan — NCT00625469bosentan — NCT01518595Bosentan — NCT00631475Bosentan — NCT00637065
Medical disclaimer. This page summarizes public trial data for NCT00071461 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.